Outcomes after Preoperative Chemoradiation with or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report from Children's Oncology Group and NRG Oncology

Aaron R. Weiss, Yen Lin Chen, Thomas J. Scharschmidt, Wei Xue, Zhengya Gao, Jennifer O. Black, Edwin Choy, Jessica L. Davis, Julie C. Fanburg-Smith, Simon C. Kao, Mark L. Kayton, Sandy Kessel, Ruth Lim, Lynn Million, Scott H. Okuno, Andrew Ostrenga, Marguerite T. Parisi, Daniel A. Pryma, R. Lor Randall, Mark A. RosenBarry L. Shulkin, Stephanie Terezakis, Rajkumar Venkatramani, Eduardo Zambrano, Dian Wang, Douglas S. Hawkins, Sheri L. Spunt

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B (P =.8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B (P =.1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.

Original languageEnglish (US)
Pages (from-to)4842-4848
Number of pages7
JournalJournal of Clinical Oncology
Volume41
Issue number31
DOIs
StatePublished - Nov 1 2023

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this